vs
塞拉尼斯（CE）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
塞拉尼斯的季度营收约是瑞思迈的1.5倍（$2.2B vs $1.4B），瑞思迈净利率更高（27.6% vs 0.6%，领先27.0%），瑞思迈同比增速更快（11.0% vs -7.0%），过去两年瑞思迈的营收复合增速更高（7.9% vs -8.1%）
塞拉尼斯是总部位于美国得克萨斯州欧文市的技术及特种材料企业，位列财富500强。公司是全球醋酸行业领军生产商，年产量约195万吨，占全球总产量的20%左右，同时也是全球最大的醋酸乙烯酯单体（VAM）供应商。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
CE vs RMD — 直观对比
营收规模更大
CE
是对方的1.5倍
$1.4B
营收增速更快
RMD
高出18.0%
-7.0%
净利率更高
RMD
高出27.0%
0.6%
两年增速更快
RMD
近两年复合增速
-8.1%
损益表 — Q4 FY2025 vs Q4 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.2B | $1.4B |
| 净利润 | $14.0M | $392.6M |
| 毛利率 | 19.1% | 61.8% |
| 营业利润率 | 4.0% | 34.6% |
| 净利率 | 0.6% | 27.6% |
| 营收同比 | -7.0% | 11.0% |
| 净利润同比 | 100.7% | 13.9% |
| 每股收益（稀释后） | $0.13 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CERMD
| Q2 26 | — | $1.4B | ||
| Q4 25 | $2.2B | $1.4B | ||
| Q3 25 | $2.4B | $1.3B | ||
| Q2 25 | $2.5B | $1.3B | ||
| Q1 25 | $2.4B | $1.3B | ||
| Q4 24 | $2.4B | $1.3B | ||
| Q3 24 | $2.6B | $1.2B | ||
| Q2 24 | $2.7B | $1.2B |
净利润CERMD
| Q2 26 | — | $392.6M | ||
| Q4 25 | $14.0M | $392.6M | ||
| Q3 25 | $-1.4B | $348.5M | ||
| Q2 25 | $199.0M | $379.7M | ||
| Q1 25 | $-21.0M | $365.0M | ||
| Q4 24 | $-1.9B | $344.6M | ||
| Q3 24 | $116.0M | $311.4M | ||
| Q2 24 | $155.0M | $292.2M |
毛利率CERMD
| Q2 26 | — | 61.8% | ||
| Q4 25 | 19.1% | 61.8% | ||
| Q3 25 | 21.5% | 61.5% | ||
| Q2 25 | 21.1% | 60.8% | ||
| Q1 25 | 19.9% | 59.3% | ||
| Q4 24 | 22.7% | 58.6% | ||
| Q3 24 | 23.5% | 58.6% | ||
| Q2 24 | 24.2% | 58.5% |
营业利润率CERMD
| Q2 26 | — | 34.6% | ||
| Q4 25 | 4.0% | 34.6% | ||
| Q3 25 | -52.7% | 33.4% | ||
| Q2 25 | 9.2% | 33.7% | ||
| Q1 25 | 7.0% | 33.0% | ||
| Q4 24 | -59.3% | 32.5% | ||
| Q3 24 | 9.4% | 31.6% | ||
| Q2 24 | 9.4% | 31.2% |
净利率CERMD
| Q2 26 | — | 27.6% | ||
| Q4 25 | 0.6% | 27.6% | ||
| Q3 25 | -56.1% | 26.1% | ||
| Q2 25 | 7.9% | 28.2% | ||
| Q1 25 | -0.9% | 28.3% | ||
| Q4 24 | -80.8% | 26.9% | ||
| Q3 24 | 4.4% | 25.4% | ||
| Q2 24 | 5.8% | 23.9% |
每股收益（稀释后）CERMD
| Q2 26 | — | $2.68 | ||
| Q4 25 | $0.13 | $2.68 | ||
| Q3 25 | $-12.39 | $2.37 | ||
| Q2 25 | $1.81 | $2.58 | ||
| Q1 25 | $-0.19 | $2.48 | ||
| Q4 24 | $-17.50 | $2.34 | ||
| Q3 24 | $1.06 | $2.11 | ||
| Q2 24 | $1.41 | $1.97 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.4B |
| 总债务越低越好 | $11.4B | $663.8M |
| 股东权益账面价值 | $4.0B | $6.3B |
| 总资产 | $21.7B | $8.5B |
| 负债/权益比越低杠杆越低 | 2.81× | 0.11× |
8季度趋势，按日历期对齐
现金及短期投资CERMD
| Q2 26 | — | $1.4B | ||
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $932.7M | ||
| Q4 24 | — | $521.9M | ||
| Q3 24 | — | $426.4M | ||
| Q2 24 | — | $238.4M |
总债务CERMD
| Q2 26 | — | $663.8M | ||
| Q4 25 | $11.4B | $403.9M | ||
| Q3 25 | $11.7B | $408.7M | ||
| Q2 25 | $12.7B | $658.4M | ||
| Q1 25 | $12.4B | $663.1M | ||
| Q4 24 | $11.1B | $662.9M | ||
| Q3 24 | $11.3B | $667.6M | ||
| Q2 24 | $11.1B | $697.3M |
股东权益CERMD
| Q2 26 | — | $6.3B | ||
| Q4 25 | $4.0B | $6.3B | ||
| Q3 25 | $4.0B | $6.1B | ||
| Q2 25 | $5.3B | $6.0B | ||
| Q1 25 | $5.2B | $5.5B | ||
| Q4 24 | $5.2B | $5.3B | ||
| Q3 24 | $7.3B | $5.2B | ||
| Q2 24 | $7.2B | $4.9B |
总资产CERMD
| Q2 26 | — | $8.5B | ||
| Q4 25 | $21.7B | $8.5B | ||
| Q3 25 | $22.2B | $8.3B | ||
| Q2 25 | $23.7B | $8.2B | ||
| Q1 25 | $23.2B | $7.6B | ||
| Q4 24 | $22.9B | $7.1B | ||
| Q3 24 | $25.9B | $7.2B | ||
| Q2 24 | $25.8B | $6.9B |
负债/权益比CERMD
| Q2 26 | — | 0.11× | ||
| Q4 25 | 2.81× | 0.06× | ||
| Q3 25 | 2.95× | 0.07× | ||
| Q2 25 | 2.41× | 0.11× | ||
| Q1 25 | 2.39× | 0.12× | ||
| Q4 24 | 2.14× | 0.13× | ||
| Q3 24 | 1.56× | 0.13× | ||
| Q2 24 | 1.54× | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $252.0M | — |
| 自由现金流经营现金流 - 资本支出 | $168.0M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 3.8% | — |
| 现金转化率经营现金流/净利润 | 18.00× | — |
| 过去12个月自由现金流最近4个季度 | $803.0M | — |
8季度趋势，按日历期对齐
经营现金流CERMD
| Q2 26 | — | — | ||
| Q4 25 | $252.0M | $339.7M | ||
| Q3 25 | $447.0M | $457.3M | ||
| Q2 25 | $410.0M | $538.8M | ||
| Q1 25 | $37.0M | $578.7M | ||
| Q4 24 | $494.0M | $308.6M | ||
| Q3 24 | $79.0M | $325.5M | ||
| Q2 24 | $292.0M | $440.1M |
自由现金流CERMD
| Q2 26 | — | — | ||
| Q4 25 | $168.0M | $311.2M | ||
| Q3 25 | $383.0M | $414.4M | ||
| Q2 25 | $317.0M | $508.2M | ||
| Q1 25 | $-65.0M | $557.9M | ||
| Q4 24 | $389.0M | $288.0M | ||
| Q3 24 | $-9.0M | $307.7M | ||
| Q2 24 | $187.0M | $415.2M |
自由现金流率CERMD
| Q2 26 | — | — | ||
| Q4 25 | 7.6% | 21.9% | ||
| Q3 25 | 15.8% | 31.0% | ||
| Q2 25 | 12.5% | 37.7% | ||
| Q1 25 | -2.7% | 43.2% | ||
| Q4 24 | 16.4% | 22.5% | ||
| Q3 24 | -0.3% | 25.1% | ||
| Q2 24 | 7.1% | 33.9% |
资本支出强度CERMD
| Q2 26 | — | — | ||
| Q4 25 | 3.8% | 2.0% | ||
| Q3 25 | 2.6% | 3.2% | ||
| Q2 25 | 3.7% | 2.3% | ||
| Q1 25 | 4.3% | 1.6% | ||
| Q4 24 | 4.4% | 1.6% | ||
| Q3 24 | 3.3% | 1.5% | ||
| Q2 24 | 4.0% | 2.0% |
现金转化率CERMD
| Q2 26 | — | — | ||
| Q4 25 | 18.00× | 0.87× | ||
| Q3 25 | — | 1.31× | ||
| Q2 25 | 2.06× | 1.42× | ||
| Q1 25 | — | 1.59× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | 0.68× | 1.05× | ||
| Q2 24 | 1.88× | 1.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CE
| Engineered Materials | $1.3B | 58% |
| Acetyl Chain | $940.0M | 43% |
RMD
暂无分部数据
